Feb 5 (Reuters) - Indian drugmaker Alembic Pharmaceuticals on Thursday reported lower third‑quarter profit on Thursday after ...
Alembic Pharmaceuticals posted double-digit revenue growth in Q3, with margins steady, though a one-time labour code ...
Motilal Oswal recommended Neutral rating on Alembic Pharma with a target price of Rs 860 in its research report dated5, 2026.
Alembic Pharmaceuticals will miss the first wave of global generic semaglutide launches but is evaluating entry into the ...
Alembic Pharmaceuticals Ltd on Friday said it has received approval from the US health regulator for its generic version of ...
The company’s decision to enter the branded US segment is driven by sustained price pressure in generics, managing director ...
The approved ANDA is therapeutically equivalent to the reference listed drug product, Durezol ophthalmic emulsion, 0.05% of ...
With this approval, Alembic’s cumulative ANDA approvals from the USFDA now stand at 234, comprising 214 final approvals and 20 tentative approvals.
Alembic Real Estate is part of the 118-year legacy of the Alembic Group, with a diversified presence spanning pharmaceuticals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results